IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Read More…
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-509-3751202
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees38
Next Earnings Date9/24/2019 (Confirmed)
OptionableNot Optionable
IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions
What is IsoRay's stock symbol?
IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."
How were IsoRay's earnings last quarter?
IsoRay, Inc. (NYSEAMERICAN:ISR) announced its quarterly earnings results on Tuesday, September, 25th. The healthcare company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The healthcare company earned $1.60 million during the quarter, compared to the consensus estimate of $1.56 million. View IsoRay's Earnings History.
When is IsoRay's next earnings date?
How can I listen to IsoRay's earnings call?
IsoRay will be holding an earnings conference call on Tuesday, September 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for ISR?
3 brokers have issued twelve-month target prices for IsoRay's stock. Their predictions range from $0.70 to $2.00. On average, they anticipate IsoRay's share price to reach $1.35 in the next year. This suggests a possible upside of 335.5% from the stock's current price. View Analyst Price Targets for IsoRay.
What is the consensus analysts' recommendation for IsoRay?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IsoRay.
What are Wall Street analysts saying about IsoRay stock?
Here are some recent quotes from research analysts about IsoRay stock:
- 1. According to Zacks Investment Research, "IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. " (7/16/2019)
- 2. HC Wainwright analysts commented, "We derive a 12-month price target of $0.70 per share based on an NPV analysis of projected product revenues through FY2030. We assume a 12.7% discount rate and a 3% terminal growth rate. We derive an NPV of $85M and add in cash and cash equivalents of $6M to arrive at a 12-month price target of $0.71, which we round to $0.70." (5/13/2019)
- 3. Maxim Group analysts commented, "IsoRay reported the September quarter (FYE: June) with Cs-131 revenue of $1.56M, down 2.5% sequentially, and flat with the Dec and Mar quarters. The company ended the period with $9.2M in cash, including net proceeds of $8.25M from a July equity financing. Our fundamental view of Cs-131 is as a superior isotope for radio-therapy remains intact though IsoRay continues to struggle to drive revenue growth. It’s still early stage for Blu-Build and the question is can GammaTile be the answer? At this point it’s too early to tell and we see only incremental revenue growth. As such, we opt to step down to a Hold rating, from Buy, remove our price target." (11/9/2018)
Has IsoRay been receiving favorable news coverage?
Headlines about ISR stock have trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. IsoRay earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the healthcare company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for IsoRay.
Who are some of IsoRay's key competitors?
Some companies that are related to IsoRay include Impression Healthcare (IHL), TSO3 (TOS), Milestone Scientific (MLSS), Daxor (DXR), G Medical (GMV), Retractable Technologies (RVP), Omega Diagnostics Group (ODX), Relevium Technologies (RLV), Akers Biosciences (AKR), Vigil Health Solutions (VGL), ANSELL LTD/S (ANSLY), CONVATEC GRP PL/ADR (CNVVY), Demant A/S (WILLF), Essilor International Cmgn Gnl D Optq (EI) and Fisher & Paykel Healthcare (FSPKF).
What other stocks do shareholders of IsoRay own?
Who are IsoRay's key executives?
IsoRay's management team includes the folowing people:
- Ms. Lori A. Holmes-Woods, CEO & Director (Age 57)
- Mr. Michael L. Krachon, VP of Sales & Marketing (Age 48)
- Mr. William A. Cavanagh III, Chief R&D Officer (Age 53)
- Mr. Jonathan R. Hunt, Co-Principal Financial Officer (Age 52)
- Mr. Mark J. Austin CPA, Controller & Co-Principal Financial Officer (Age 32)
Who are IsoRay's major shareholders?
IsoRay's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.37%). Company insiders that own IsoRay stock include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, Thomas C Lavoy and William Cavanagh. View Institutional Ownership Trends for IsoRay.
Which major investors are buying IsoRay stock?
ISR stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought IsoRay stock in the last two years include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, Thomas C Lavoy and William Cavanagh. View Insider Buying and Selling for IsoRay.
How do I buy shares of IsoRay?
Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IsoRay's stock price today?
One share of ISR stock can currently be purchased for approximately $0.31.
How big of a company is IsoRay?
What is IsoRay's official website?
How can I contact IsoRay?
IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.
MarketBeat Community Rating for IsoRay (NYSEAMERICAN ISR)
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe ISR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISR will underperform the S&P 500 over the long term. You may vote once every thirty days.
